Avesta Biotherapeutics

Avesta Biotherapeutics is a clinical-stage biotechnology company focused on the development of off-the-shelf Natural Killer (NK) cell therapies for the treatment of various cancers. The company's platform utilizes umbilical cord blood as a source for NK cells, which are then engineered to improve their efficacy, persistence, and targeting capabilities. By providing an allogeneic, ready-to-use product, Avesta aims to reduce the cost and complexity associated with patient-specific cell therapies like traditional CAR-T. Their lead programs are currently in clinical trials for hematologic malignancies, with additional research focused on expanding the platform to treat solid tumors. The company is a spin-out from the University of Texas MD Anderson Cancer Center, leveraging the pioneering research of Dr. Katy Rezvani.